Literature DB >> 26928252

Comment on Lipsky et al.: Incidence and Risk Factors of Bleeding-Related Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib.

Constantine S Tam1, Sarah Kamel2.   

Abstract

Entities:  

Keywords:  chronic lymphocytic leukemia; lymphocytes; platelets

Mesh：

Year:  2016        PMID： 26928252      PMCID： PMC4815744          DOI： 10.3324/haematol.2015.139030

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  6 in total

1.  Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib.

Authors:  Andrew H Lipsky; Mohammed Z H Farooqui; Xin Tian; Sabrina Martyr; Ann M Cullinane; Khanh Nghiem; Clare Sun; Janet Valdez; Carsten U Niemann; Sarah E M Herman; Nakhle Saba; Susan Soto; Gerald Marti; Gulbu Uzel; Steve M Holland; Jay N Lozier; Adrian Wiestner
Journal:  Haematologica       Date:  2015-10-01       Impact factor: 9.941

2.  Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation.

Authors:  S Kamel; L Horton; L Ysebaert; M Levade; K Burbury; S Tan; M Cole-Sinclair; J Reynolds; R Filshie; S Schischka; A Khot; S Sandhu; M J Keating; H Nandurkar; C S Tam
Journal:  Leukemia       Date:  2014-08-20       Impact factor: 11.528

3.  Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

Authors:  John C Byrd; Jennifer R Brown; Susan O'Brien; Jacqueline C Barrientos; Neil E Kay; Nishitha M Reddy; Steven Coutre; Constantine S Tam; Stephen P Mulligan; Ulrich Jaeger; Steve Devereux; Paul M Barr; Richard R Furman; Thomas J Kipps; Florence Cymbalista; Christopher Pocock; Patrick Thornton; Federico Caligaris-Cappio; Tadeusz Robak; Julio Delgado; Stephen J Schuster; Marco Montillo; Anna Schuh; Sven de Vos; Devinder Gill; Adrian Bloor; Claire Dearden; Carol Moreno; Jeffrey J Jones; Alvina D Chu; Maria Fardis; Jesse McGreivy; Fong Clow; Danelle F James; Peter Hillmen
Journal:  N Engl J Med       Date:  2014-05-31       Impact factor: 91.245

4.  Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions.

Authors:  Marie Levade; Elodie David; Cédric Garcia; Pierre-Alexandre Laurent; Sarah Cadot; Anne-Sophie Michallet; Jean-Claude Bordet; Constantine Tam; Pierre Sié; Loïc Ysebaert; Bernard Payrastre
Journal:  Blood       Date:  2014-10-10       Impact factor: 22.113

5.  Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

Authors:  John C Byrd; Richard R Furman; Steven E Coutre; Ian W Flinn; Jan A Burger; Kristie A Blum; Barbara Grant; Jeff P Sharman; Morton Coleman; William G Wierda; Jeffrey A Jones; Weiqiang Zhao; Nyla A Heerema; Amy J Johnson; Juthamas Sukbuntherng; Betty Y Chang; Fong Clow; Eric Hedrick; Joseph J Buggy; Danelle F James; Susan O'Brien
Journal:  N Engl J Med       Date:  2013-06-19       Impact factor: 91.245

6.  Ibrutinib in relapsed chronic lymphocytic leukemia.

Authors:  Stuart A Rushworth; David J MacEwan; Kristian M Bowles
Journal:  N Engl J Med       Date:  2013-09-26       Impact factor: 91.245
  6 in total
  1 in total

1.  Ibrutinib does not affect ristocetin-induced platelet aggregation evaluated by light transmission aggregometry in chronic lymphocytic leukemia patients.

Authors:  Maria Adele Alberelli; Idanna Innocenti; Francesco Autore; Luca Laurenti; Erica De Candia
Journal:  Haematologica       Date:  2017-12-14       Impact factor: 9.941
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.